Table 1 |
|
| Patient characteristics | |
| CHARACTERISTIC | |
| Age: Median (range) | 61years (46–74 years) |
| Male | 26 (58%) |
| Female | 19 (42%) |
| Significant Bone disease1 | 23 (51%) |
| Time following completion of treatment | 11months (median) |
| (range 3–149 months) | |
| Previous ASCT2 | 42 (93%) |
| Previous orthopaedic surgery | 6 (13%) |
| Current therapies | |
| Maintenance treatment | 9 (20%) |
| • Lenalidomide | 1 |
| • Interferon | 2 |
| • Thalidomide | 6 |
| Regular analgesia | 11 (24%) |
Details are given of patient characteristics for the 45 patients who completed baseline screening.
1 with one or more of the following: bone pain, vertebral collapse, fractures.
2 autologous stem cell transplantation.
Groeneveldt et al. BMC Cancer 2013 13:31 doi:10.1186/1471-2407-13-31
